Degarelix Research Dosage: Published Protocol Reference
Degarelix dosage references vary by route and study context. The database lists Subcutaneous injection: 240 mg (loading dose), Once (first dose) and Subcutaneous injection: 80 mg, Every 28 days (maintenance). These are research-context references, not a universal protocol.
Direct Answer
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology
Research Dosage References
- <strong>Subcutaneous injection</strong> - 240 mg (loading dose) - Once (first dose) - Loading dose administered as two 120 mg injections at different abdominal sites.
- <strong>Subcutaneous injection</strong> - 80 mg - Every 28 days (maintenance) - Maintenance dosing begins 28 days after loading dose. Administered in the abdominal area.
Half-Life
~43-53 days (due to depot formation).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Degarelix, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Injection site reactions occur in ~40% of patients
- QT prolongation possible - monitor ECG in at-risk patients
- Hyperglycemia and diabetes risk with long-term androgen deprivation
- Bone density loss with prolonged therapy
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Testosterone Suppression (Level A), Prostate Cancer Control (Level A), and Cardiovascular Events (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Degarelix Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/degarelix-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.